A detailed history of Lokken Investment Group LLC transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Lokken Investment Group LLC holds 12,235 shares of ANVS stock, worth $69,250. This represents 0.04% of its overall portfolio holdings.

Number of Shares
12,235
Previous 12,235 -0.0%
Holding current value
$69,250
Previous $70,000 40.0%
% of portfolio
0.04%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$8.47 - $18.93 $103,630 - $231,608
12,235 New
12,235 $145,000
Q2 2021

Aug 03, 2021

SELL
$21.55 - $96.1 $375,207 - $1.67 Million
-17,411 Closed
0 $0
Q1 2021

Jun 10, 2021

SELL
$8.15 - $38.44 $120,620 - $568,912
-14,800 Reduced 45.95%
17,411 $486,000
Q4 2020

Feb 08, 2021

BUY
$4.36 - $7.54 $64,528 - $111,592
14,800 Added 85.0%
32,211 $243,000
Q1 2012

Apr 13, 2021

BUY
N/A
17,411
17,411 $486,000

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $46.2M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Lokken Investment Group LLC Portfolio

Follow Lokken Investment Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lokken Investment Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lokken Investment Group LLC with notifications on news.